Allena Pharmaceuticals (NASDAQ:ALNA) versus Applied Genetic Technologies (AGTC) Financial Contrast

Allena Pharmaceuticals (NASDAQ:ALNA) and Applied Genetic Technologies (NASDAQ:AGTC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends.

Volatility and Risk

Allena Pharmaceuticals has a beta of 1.87, suggesting that its stock price is 87% more volatile than the S&P 500. Comparatively, Applied Genetic Technologies has a beta of 2.86, suggesting that its stock price is 186% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Allena Pharmaceuticals and Applied Genetic Technologies, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Allena Pharmaceuticals 0 0 6 0 3.00
Applied Genetic Technologies 0 2 2 0 2.50

Allena Pharmaceuticals currently has a consensus price target of $25.20, suggesting a potential upside of 296.85%. Applied Genetic Technologies has a consensus price target of $7.75, suggesting a potential upside of 70.33%. Given Allena Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Allena Pharmaceuticals is more favorable than Applied Genetic Technologies.

Valuation & Earnings

This table compares Allena Pharmaceuticals and Applied Genetic Technologies’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Allena Pharmaceuticals N/A N/A -$35.65 million ($1.72) -3.69
Applied Genetic Technologies $24.19 million 3.42 -$21.30 million ($1.18) -3.86

Applied Genetic Technologies has higher revenue and earnings than Allena Pharmaceuticals. Applied Genetic Technologies is trading at a lower price-to-earnings ratio than Allena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

80.1% of Allena Pharmaceuticals shares are owned by institutional investors. Comparatively, 43.0% of Applied Genetic Technologies shares are owned by institutional investors. 36.7% of Allena Pharmaceuticals shares are owned by company insiders. Comparatively, 6.9% of Applied Genetic Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Allena Pharmaceuticals and Applied Genetic Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Allena Pharmaceuticals N/A -56.89% -46.56%
Applied Genetic Technologies -61.04% -19.73% -15.08%

Summary

Allena Pharmaceuticals beats Applied Genetic Technologies on 7 of the 13 factors compared between the two stocks.

Allena Pharmaceuticals Company Profile

Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is headquartered in Newton, Massachusetts.

Applied Genetic Technologies Company Profile

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It has collaboration agreements with Biogen MA, Inc., Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation. The company was founded in 1999 and is headquartered in Alachua, Florida.

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.